Horizon Pharma (HZNP) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Horizon Pharma Plc (HZNP) Should Benefit From M&A - Mizuho
May 10, 2016 6:37 AM EDTMizuho analyst, Irina Koffler, trimmed her PT on Horizon Pharma (NASDAQ: HZNP) to $24 from $25 while maintaining her Buy rating. Despite seeing a challenging 2016, she thinks the company should benefit from M&A making the risk/reward is still attractive.
HZNP reported 1Q:16... More
